The product is a potent inhibitor of both mTORC1 and mTORC2 complexes, affecting the PI3K/AKT/mTOR pathway. It demonstrates the ability to reduce endothelial cell proliferation and induce apoptosis in vitro, as well as exhibit antitumor activity in various cancer cell lines and mouse models. This compound interferes with the pathway through the dissociation of mTOR complex 1 and mTOR complex 2, leading to decreased phosphorylation of substrates, cell growth inhibition, and cell death.
- Potent inhibitor of mTORC1 and mTORC2 complexes.
- Inhibits VEGF-driven and bFGF-driven endothelial cell proliferation.
- Induces endothelial cell apoptosis.
- Reduces Akt activity in various cancer cell lines.
- Demonstrates antitumor activity in glioblastoma, prostate, and breast cancer models.
- Causes cell growth inhibition and death in cancer cells.